Overview
Okihiro syndrome due to 20q13 microdeletion is a rare genetic condition caused by a chromosomal microdeletion on the long arm of chromosome 20 (20q13) that encompasses the SALL4 gene. This condition is a specific genetic subtype of Okihiro syndrome, also known as Duane-radial ray syndrome (DRRS) or acro-renal-ocular syndrome. It is characterized by the combination of Duane anomaly (a congenital eye movement disorder affecting the ability to move the eye outward, and sometimes inward, due to abnormal innervation of the eye muscles) and upper limb malformations, particularly radial ray defects. Radial ray abnormalities can range from mild thumb hypoplasia or triphalangeal thumbs to complete absence of the thumb or radius. The syndrome can affect multiple body systems beyond the eyes and limbs. Patients may present with renal anomalies (such as kidney malformations or ectopic kidneys), hearing loss (sensorineural or conductive), cardiac defects, and anorectal malformations. The severity and combination of features can vary considerably, even among affected members of the same family. Some individuals may have subtle findings, while others can be more significantly affected. Because this form is caused by a microdeletion rather than a point mutation in SALL4, affected individuals may occasionally exhibit additional features related to the loss of neighboring genes (contiguous gene deletion syndrome). Management is multidisciplinary and symptom-based, involving orthopedic surgery for limb anomalies, ophthalmologic monitoring for Duane anomaly, audiologic evaluation, cardiac assessment, and renal imaging. There is currently no cure or disease-specific therapy; treatment focuses on surgical correction and supportive care tailored to each patient's clinical presentation. Genetic counseling is recommended for affected families.
Also known as:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Okihiro syndrome due to 20q13 microdeletion.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Okihiro syndrome due to 20q13 microdeletion at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Okihiro syndrome due to 20q13 microdeletion.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Okihiro syndrome due to 20q13 microdeletion.
Community
No community posts yet. Be the first to share your experience with Okihiro syndrome due to 20q13 microdeletion.
Start the conversation →Latest news about Okihiro syndrome due to 20q13 microdeletion
No recent news articles for Okihiro syndrome due to 20q13 microdeletion.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Okihiro syndrome due to 20q13 microdeletion
What is Okihiro syndrome due to 20q13 microdeletion?
Okihiro syndrome due to 20q13 microdeletion is a rare genetic condition caused by a chromosomal microdeletion on the long arm of chromosome 20 (20q13) that encompasses the SALL4 gene. This condition is a specific genetic subtype of Okihiro syndrome, also known as Duane-radial ray syndrome (DRRS) or acro-renal-ocular syndrome. It is characterized by the combination of Duane anomaly (a congenital eye movement disorder affecting the ability to move the eye outward, and sometimes inward, due to abnormal innervation of the eye muscles) and upper limb malformations, particularly radial ray defects.
How is Okihiro syndrome due to 20q13 microdeletion inherited?
Okihiro syndrome due to 20q13 microdeletion follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Okihiro syndrome due to 20q13 microdeletion typically begin?
Typical onset of Okihiro syndrome due to 20q13 microdeletion is neonatal. Age of onset can vary across affected individuals.